S
Malvinder Singh
CEO, Ranbaxy Labs
RANK: No. 28 on Forbes' list of richest Indians (with brother Shivinder)
GOAL: To grow Ranbaxy to a $5 billion dollar company by 2012
For Malvinder Singh, age 35, Ranbaxy was never just a business. It's family. "My grandfather started the company in the early '60s," he explains. "My father was a PhD in pharmacy, and the two of them built the company together. From my childhood, they were living and breathing Ranbaxy. I would visit doctors, learn things, meet people."
Malvinder Singh
In 1994, his father took him on as a management trainee, starting him at the bottom of the ladder, and paying him less than other trainees to ensure he got no favoritism. Singh left briefly to pursue his MBA at Duke, but returned in 1998.
"My father was diagnosed with cancer," he says. "I could have had a job as an investment banker, but it was important for me to be with India with him. It was time to come back and join the company."
Today, as CEO, Singh is carrying on his father's goals of making Ranbaxy a truly global pharma company, extending the firm's customer base, making significant acquisitions, and forging high- profile deals with Big Pharma. "Big Pharma is in trouble," says Singh. "I see very substantial alliance partnerships with Big Pharma in the areas of biotech and supply chain and R&D, where we can partner and add value."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.